What is the recommended management for symptomatic Candida urinary tract infection, including catheter removal and appropriate antifungal therapy?

Management of Candida UTI

Remove the urinary catheter immediately if present, and only treat with antifungals if the patient is symptomatic, neutropenic, a very low-birth-weight infant, or undergoing urologic procedures. Most candiduria represents asymptomatic colonization that does not require antifungal therapy 1.

Key Decision Point: Who Needs Treatment?

The fundamental management principle is that antifungal therapy is NOT recommended for asymptomatic candiduria except in three high-risk groups 1:

• Neutropenic patients (treat as candidemia)
• Very low-birth-weight infants <1500g (treat as candidemia)
• Patients undergoing urologic procedures (prophylactic treatment perioperatively)

This approach prevents unnecessary antibiotic exposure and reduces the risk of resistance development, which research confirms is a major problem in clinical practice where overtreatment of asymptomatic candiduria remains common 2.

Source Control: The Critical First Step

Catheter removal is strongly recommended and should be done as early as feasible 1. This single intervention clears candiduria in approximately 50% of asymptomatic patients without any antifungal therapy 3. For patients with urinary obstruction, nephrostomy tubes, or stents, consider removal or replacement if possible 1.

Antifungal Therapy for Symptomatic Infections

Candida Cystitis (Lower UTI)

For fluconazole-susceptible species (most C. albicans):

• Oral fluconazole 200 mg (3 mg/kg) daily for 2 weeks 1
• This is a strong recommendation with moderate-quality evidence

For fluconazole-resistant C. glabrata:

• Amphotericin B deoxycholate 0.3-0.6 mg/kg daily for 1-7 days OR
• Oral flucytosine 25 mg/kg four times daily for 7-10 days 1
• Consider amphotericin B bladder irrigation (50 mg/L sterile water daily for 5 days) as adjunctive therapy 1

For C. krusei:

• Amphotericin B deoxycholate 0.3-0.6 mg/kg daily for 1-7 days 1

Candida Pyelonephritis (Upper UTI)

For fluconazole-susceptible organisms:

• Oral fluconazole 200-400 mg (3-6 mg/kg) daily for 2 weeks 1

For fluconazole-resistant C. glabrata:

• Amphotericin B deoxycholate 0.3-0.6 mg/kg daily for 1-7 days with or without oral flucytosine 25 mg/kg four times daily 1
• Monotherapy with flucytosine 25 mg/kg four times daily for 2 weeks can be considered (weaker recommendation) 1

Eliminate urinary tract obstruction - this is strongly recommended and critical for treatment success 1.

Treatment Duration Considerations

Recent 2025 data suggests that shorter durations may be equally effective. A retrospective study found no difference in clinical success between 14 days versus a median of 7 days of fluconazole for symptomatic Candida UTI (93.3% vs 93.1% success rates) 4. However, the established guideline recommendation remains 14 days, and this newer evidence requires validation in prospective trials before changing practice standards.

Perioperative Prophylaxis

For patients undergoing urologic procedures with candiduria:

• Fluconazole 400 mg (6 mg/kg) daily OR
• Amphotericin B deoxycholate 0.3-0.6 mg/kg daily
• Give for several days before AND after the procedure 1

Critical Pitfalls to Avoid

Do not use echinocandins or non-fluconazole azoles for urinary tract infections - they achieve inadequate urinary concentrations and are ineffective 5, 3, 6. This includes voriconazole, posaconazole, itraconazole, caspofungin, micafungin, and anidulafungin.

Do not treat asymptomatic candiduria in immunocompetent patients - this leads to unnecessary antifungal exposure, increased costs, and potential resistance development without clinical benefit 2, 5.

Always obtain susceptibility testing to guide therapy, particularly given rising rates of non-albicans species with azole resistance 1, 5.

Consider disseminated candidiasis in high-risk patients (neutropenic, ICU patients, recent abdominal surgery) as candiduria may be the only indicator of invasive disease 5, 6, 7. Recent data shows 20.8% of candidemia cases originate from the urinary tract, particularly in elderly patients with bladder catheters or urologic procedures 7.

Special Populations

Neutropenic patients and very low-birth-weight infants with candiduria should be treated as candidemia with systemic antifungal therapy, not just as isolated UTI 1. This reflects the high risk of dissemination in these vulnerable populations.